Improvements in Survival After Follicular Lymphoma by Race/Ethnicity and Socioeconomic Status: A Population-Based Study
- 20 June 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (18), 3044-3051
- https://doi.org/10.1200/jco.2008.18.8052
Abstract
A recent report suggested improvements in survival after follicular lymphoma (FL), but not for all racial/ethnic groups. To better understand the reasons for these FL survival differences, we examined the joint influences of diagnostic period, race/ethnicity, and neighborhood socioeconomic status (SES) on survival in a large population-based case series. All patients (n = 15,937) diagnosed with FL between 1988 and 2005 in California were observed for vital status through November 2007. Overall and FL-specific survival were analyzed with Kaplan-Meier and Cox proportional hazards regression. Neighborhood SES was assigned from United States Census data using residence at diagnosis. Overall and FL-specific survival improved 22% and 37%, respectively, from 1988 to 1997 to 1998 to 2005, and were observed in all racial/ethnic groups. Asian/Pacific Islanders had better survival than non-Hispanic white, Hispanic, and black patients who had similar outcomes. Lower neighborhood SES was associated with worse survival in patients across all stages of disease (P for trend < .01). Patients with the lowest SES quintile had a 49% increased risk of death from all causes (hazard ratio [HR] = 1.49, 95% CI, 1.30 to 1.72) and 31% increased risk of death from FL (HR = 1.31; 95% CI, 1.06 to 1.60) than patients with the highest SES. Evolving therapies have likely led to improvements in survival after FL. Although improvements have occurred within all racial/ethnic groups, lower neighborhood SES was significantly associated with substantially poorer survival.Keywords
This publication has 41 references indexed in Scilit:
- Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph)Blood, 2007
- Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology StudyJournal of Clinical Oncology, 2007
- Introduction of rituximab in front‐line and salvage therapies has improved outcome of advanced‐stage follicular lymphoma patientsCancer, 2007
- Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study GroupBlood, 2005
- New Treatment Options Have Changed the Survival of Patients With Follicular LymphomaJournal of Clinical Oncology, 2005
- Epstein-Barr Virus As a Marker of Survival After Hodgkin's Lymphoma: A Population-Based StudyJournal of Clinical Oncology, 2005
- Central nervous system chemoprophylaxis in non‐Hodgkin lymphoma: current practice in the UKBritish Journal of Haematology, 2005
- Improved Survival of Follicular Lymphoma Patients in the United StatesJournal of Clinical Oncology, 2005
- Neighborhood Socioeconomic Status and Hodgkin's Lymphoma Incidence in CaliforniaCancer Epidemiology, Biomarkers & Prevention, 2005
- Prolonged disease-free survival in relapsed/refractory low-grade lymphoma treated with fludarabine: a report of four casesBritish Journal of Haematology, 1998